1. Spain Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Pharma Mar S.A.

Pharma Mar S.A.

0RC6.IL
Pharma Mar S.A.GB flagInternational Order Book
82.40
EUR
-1.17
- -
1.43BMarket Cap
Pharma Mar S.A.
0RC6.IL
(International Order Book)

Recent

price

82.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
8.36
8.3
7.41
7.65
9.5
10.49
9.84
8.64
5.91
4.65
14.76
12.72
10.88
8.84
9.97
12.7
13.47
Revenue per Share
-0.67
0.26
0.36
0.62
0.72
0.36
-1.31
-1.45
-0.3
-0.62
7.5
5.14
2.73
0.06
1.49
4.3
2.63
Basic EPS, GAAP
-1.36
-0.4
0.34
1.01
1.24
0.6
-0.46
-0.08
-0.91
-1.53
15.08
0.99
1.63
-1.64
-0.54
2.51
0.1
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.48
0.6
0.65
0.65
0.65
0.8
- -
Dividend per Share
1.91
2.14
2.31
2.9
3.5
4.17
2.84
1.46
1.16
0.61
5.67
9.88
12.31
10.97
11.86
14.51
11.56
Book Value per Share
0.99
1.06
1.09
1.53
1.92
2.58
1.35
0.22
0.12
0.29
5.46
9.7
12.17
10.86
11.8
14.3
11.5
Tangible Book Value per Share
18
18
18
18
18
18
18
18
18
18
18
18
18
18
18
17
17
Basic Weighted Avg Shares
154
152
136
140
174
193
181
159
109
86
270
230
196
158
175
221
235
Sales/Revenue/Turnover
-6.2
15.64
10.68
13.49
11.63
5.86
-10.34
-12.3
-14.74
-20.36
57.86
40.18
22.63
-2.48
3.44
27.08
15.58
Operating Margin (%)
5
6
6
5
5
6
7
7
6
8
7
6
6
6
7
8
8
Depreciation Expense
-12
5
7
11
13
7
-24
-27
-6
-11
137
93
49
1
26
75
46
Net Income, GAAP
- -
13.97
- -
14.2
9.01
- -
- -
- -
- -
- -
5.73
2.39
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-8.03
3.11
4.84
8.06
7.54
3.42
-13.31
-16.84
-5.09
-13.26
50.85
40.4
25.14
0.72
14.94
33.87
19.54
Profit Margin (%)
40
40
20
22
19
42
34
10
3
-10
151
209
178
157
168
190
162
Working Capital
85
83
62
53
47
65
68
74
65
55
40
35
28
29
41
37
39
LT Debt
35
35
39
49
60
73
48
23
17
7
103
178
223
193
208
252
202
Total Equity
- -
11.63
- -
10.89
12.5
- -
- -
- -
- -
- -
116.75
46.72
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
9.31
- -
11.39
12.84
- -
- -
- -
- -
- -
110.85
49.74
- -
- -
- -
- -
- -
Return on Capital (%)
-32.31
12.68
16.1
23.7
22.4
9.36
-37.27
-67.52
-22.95
-69.5
240.61
66.18
24.62
0.55
13
32.59
23.98
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
10
12
12
LT Borrowings
40
39
38
LT Finance Leases
1
2
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
18
17
17
Market Capitalization
1,399
1,414
1,387

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
250
236
249
Cash, Cash Equivalents & STI
155
141
128
Accounts Receivable, Net
34
37
38
Inventories
51
51
50
Total Current Liabilities
83
79
88
Payables & Accruals
- -
- -
- -
ST Debt
10
12
12
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
122.4%
22.77%
20.86%
Free Cash Flow
-107.49%
-171.51%
-561.36%
Net Income, GAAP
47.34%
441.57%
187.03%
Sales/Revenue/Turnover
13.18%
-2.34%
26.61%
Total Cash Common Dividend
- -
10.14%
22.15%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
38
43
46
94
175
2025
39
56
128
- -
221
2026
43
50
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.13
- -
- -
1.29
1.49
2025
-0.23
- -
3.2
- -
4.3
2026
0.09
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.65
2025
- -
- -
- -
- -
0.8
2026
- -
- -
- -
- -
- -
Similar Companies
Sibannac, Inc. (SNNC)
MDxHealth S.A. (0O8G.L)
Hanshang Group Co., Ltd. (600774.SS)
SymBio Pharmaceuticals Limited (SYMQY)
Targeted Medical Pharma, Inc. (TRGM)
Recordati S.p.A. (RCDTF)
Business
PharmaMar S.A. is a Spain-based biopharmaceutical company focused on the discovery, development, and commercialization of novel anticancer medicines derived from marine organisms and related biotechnologies; it specializes in oncology therapeutics, including marine-derived compounds and targeted therapies, with a portfolio spanning clinical and preclinical candidates and companion diagnostics, alongside research and development services for collaborative programs. PharmaMar operates primarily in Europe, the Americas, and other international markets, with commercial activities in Spain and select European Union countries, and maintains research facilities and manufacturing capabilities in Spain. Main products and services: marine-derived anticancer agents including small-molecule and biologic oncology therapeutics; drug discovery and development services; preclinical and clinical trial collaborations; supply and distribution of approved oncology medicines; research collaborations and licensing of pipeline assets; companion diagnostics development; regulatory and pharmacovigilance support; manufacturing and formulation development; API production and specialty pharmaceutical services; commercialization and marketing of oncology products in selected geographies. Latest major company changes: enters strategic partnerships and licensing agreements to advance pipeline candidates; completes acquisitions or divestitures related to portfolio optimization; launches new oncology products or expands indications; reorganizations or corporate restructurings to focus on core oncology platform; expands geographic footprint or distribution capabilities; initiates significant operational expansions in R&D and GMP manufacturing capacity. Industry and segments: biopharmaceuticals; oncology; research and development; clinical-stage and mid-to-late-stage oncology assets; licensing and collaboration services; manufacturing and supply chain for oncology medicines. Target markets and customers: healthcare providers, hospitals, and oncology specialists; pharmaceutical distributors; research institutions and biopharma partners; patient populations across Europe and the Americas requiring cancer therapeutics. Subsidiaries/parent relationships: operates as PharmaMar S.A. with parent or group company relationships in the corporate structure; maintains affiliated R&D centers and manufacturing sites in Spain as part of its integrated oncology platform.